Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Natalizumab (Tysabri).

Literature DB >> 20688889

Natalizumab (Tysabri).

D T Selewski¹, G V Shah, B M Segal, P A Rajdev, S K Mukherji.

Abstract

Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.

Entities: Chemical

Mesh：

Substances：

Year: 2010 PMID： 20688889 PMCID： PMC7964985 DOI： 10.3174/ajnr.A2226

Source DB: PubMed Journal: AJNR Am J Neuroradiol ISSN： 0195-6108 Impact factor: 3.825

17 in total

1. Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis.

Authors: Azza Ismail; Julie Kemp; Basil Sharrack
Journal: J Neurol Date: 2009-07-16 Impact factor: 4.849

Review 2. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors: David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal: Lancet Neurol Date: 2010-04 Impact factor: 44.182

3. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment.

Authors: S Brocke; C Piercy; L Steinman; I L Weissman; T Veromaa
Journal: Proc Natl Acad Sci U S A Date: 1999-06-08 Impact factor: 11.205

4. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

Authors: F H Gordon; C W Lai; M I Hamilton; M C Allison; E D Srivastava; M G Fouweather; S Donoghue; C Greenlees; J Subhani; P L Amlot; R E Pounder
Journal: Gastroenterology Date: 2001-08 Impact factor: 22.682

5. Natalizumab induction and maintenance therapy for Crohn's disease.

Authors: William J Sandborn; Jean Frédéric Colombel; Roberts Enns; Brian G Feagan; Stephen B Hanauer; Ian C Lawrance; Remo Panaccione; Martin Sanders; Stefan Schreiber; Stephan Targan; Sander van Deventer; Ronald Goldblum; Darrin Despain; Gary S Hogge; Paul Rutgeerts
Journal: N Engl J Med Date: 2005-11-03 Impact factor: 91.245

Review 6. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors: D S Goodin; B A Cohen; P O'Connor; L Kappos; J C Stevens
Journal: Neurology Date: 2008-09-02 Impact factor: 9.910

7. Natalizumab for active Crohn's disease.

Authors: Subrata Ghosh; Eran Goldin; Fiona H Gordon; Helmut A Malchow; Jørgen Rask-Madsen; Paul Rutgeerts; Petr Vyhnálek; Zdena Zádorová; Tanya Palmer; Stephen Donoghue
Journal: N Engl J Med Date: 2003-01-02 Impact factor: 91.245

8. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors: Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245

9. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors: Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245

10. A controlled trial of natalizumab for relapsing multiple sclerosis.

Authors: David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor
Journal: N Engl J Med Date: 2003-01-02 Impact factor: 91.245

18 in total

Review 1. Have we overestimated the benefit of human(ized) antibodies?

Authors: Daniel R Getts; Meghann T Getts; Derrick P McCarthy; Emily M L Chastain; Stephen D Miller
Journal: MAbs Date: 2010-11-01 Impact factor: 5.857

2. Editorial: cell movement.

Authors: S Detchokul; A G Frauman
Journal: Br J Pharmacol Date: 2014-12 Impact factor: 8.739

3. Diffusion tensor MRI as a biomarker in axonal and myelin damage.

Authors: Wint Yan Aung; Soe Mar; Tammie Ls Benzinger
Journal: Imaging Med Date: 2013-10-01

Review 4. Recent Advances in the Treatment for Multiple Sclerosis; Current New Drugs Specific for Multiple Sclerosis.

Authors: ÖZlem TaŞKapilioĞLu
Journal: Noro Psikiyatr Ars Date: 2018 Impact factor: 1.339

5. An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family.

Authors: Céline Cegarra; Béatrice Cameron; Catarina Chaves; Tarik Dabdoubi; Tuan-Minh Do; Bruno Genêt; Valérie Roudières; Yi Shi; Patricia Tchepikoff; Dominique Lesuisse
Journal: PLoS One Date: 2022-09-15 Impact factor: 3.752

6. Antisense modulation of IL7R splicing to control sIL7R expression in human CD4⁺ T cells.

Authors: Gaddiel Galarza-Muñoz; Debbie Kennedy-Boone; Geraldine Schott; Shelton S Bradrick; Mariano A Garcia-Blanco
Journal: RNA Date: 2022-05-25 Impact factor: 5.636

Review 7. Encephalitogenic and Regulatory CD8 T Cells in Multiple Sclerosis and Its Animal Models.

Authors: Taryn E Mockus; Ashley Munie; Jeffrey R Atkinson; Benjamin M Segal
Journal: J Immunol Date: 2021-01-01 Impact factor: 5.422

Review 8. Early implementation of QbD in biopharmaceutical development: a practical example.

Authors: Jesús Zurdo; Andreas Arnell; Olga Obrezanova; Noel Smith; Ramón Gómez de la Cuesta; Thomas R A Gallagher; Rebecca Michael; Yvette Stallwood; Caroline Ekblad; Lars Abrahmsén; Ingmarie Höidén-Guthenberg
Journal: Biomed Res Int Date: 2015-05-17 Impact factor: 3.411

9. Treatment of experimental autoimmune encephalomyelitis by codelivery of disease associated Peptide and dexamethasone in acetalated dextran microparticles.

Authors: Kevin J Peine; Mireia Guerau-de-Arellano; Priscilla Lee; Naveen Kanthamneni; Mary Severin; G Duane Probst; Haiyan Peng; Yuhong Yang; Zachary Vangundy; Tracey L Papenfuss; Amy E Lovett-Racke; Eric M Bachelder; Kristy M Ainslie
Journal: Mol Pharm Date: 2014-02-04 Impact factor: 4.939

Review 10. Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us?

Authors: Matías Sáenz-Cuesta; Iñaki Osorio-Querejeta; David Otaegui
Journal: Front Cell Neurosci Date: 2014-03-28 Impact factor: 5.505